Abstract
BACKGROUND: Sepsis is the most common cause of death in hospitalized cancer patients. Iron metabolism is one system that is strongly influenced by severe infectious and inflammatory conditions. AIM: This study aims to determine the difference in survival based on hepcidin levels in surviving and non-surviving cancer patients with sepsis. METHODS: This study is a cohort study in solid and hematological cancer patients with sepsis aged 18 years and older who were hospitalized from February to June 2022. The criteria for sepsis are the presence of infection accompanied by a Sequential Organ Failure Assessment (SOFA) score of two points or more. A total of 40 samples were included in this study. RESULTS: We found different survival curves in subjects with high hepcidin levels compared to subjects with low hepcidin levels. The hazard ratio (HR) of hepcidin levels was 7.28 (95% confidence interval (CI) 2.35–22.55), p<0.001. In multivariate analysis, hepcidin levels had an adjusted HR of 7.91 (2.51–24.91), p < 0.001. CONCLUSIONS: From the results of this study, it can be concluded that cancer patients with sepsis who have high hepcidin levels have lower survival than patients with low hepcidin levels at 28-day follow-up.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call